Screening potential therapies: Lessons learned from new paradigms used in Parkinson disease

Stroke

Volumn 38, Issue 2 PART 2, 2007, Pages 800-803

  Tilley, Barbara C ^a   Galpern, Wendy R ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Futility studies; Parkinson disease; Phase II clinical trials; Stroke

Indexed keywords

SELEGILINE; TOCOPHEROL;

BLOOD BRAIN BARRIER; CONFERENCE PAPER; DATA BASE; HUMAN; NEUROPROTECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; STROKE;

ADVISORY COMMITTEES; ANTIPARKINSON AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; UNITED STATES;

EID: 33846641246     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000255227.96365.37     Document Type: Conference Paper

References (23)

1. The National Institute of Neurological Disorders; Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
3. Qureshi AI, Kirmani JF, Sayed MA, Safdar A, Ahmed S, Ferguson R, Hershey LA, Qazi KJ. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology. 2005;64:2115-2120.
4. Sacchetti ML, Toni D, Fiorelli M, Angentino C, Fieschi C. The concept of combination therapy in acute ischemic stroke. Neurology. 1997;49 (Suppl 4):S70-S74.
5. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60:1234-1240.
6. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC; on behalf of the NET-PD Investigators. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006;66:628-633.
7. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch Y, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K. A responsive outcome for Parkinson's Disease neuroprotection futility studies. Ann Neurol. 2005;57:197-203.
8. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's Disease. N Engl J Med. 1993;328:176-183.
9. Herson J, Carter SK. Calibrated phase II clinical trials in oncology. Stat Medicine. 1986;5:441-447.
10. Holloway RG, Dick AW. Clinical trial endpoints: on the road to nowhere. Neurology. 2002;58:679-686.
11. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664-671.
12. 10 and GPI-1485 in early Parkinson's disease. Neurology. 2007; 68:20-28.
13. The Parkinson Study Group PRECEPT Investigators. Baseline comparison of the PRECEPT and DATATOP Clinical Trial Cohorts (abstract). Movement Disorders. 206;21(suppl 13):S121.
14. The Parkinson's Disease Data and Organizing Center (PDDOC). Available at: http://dev.pd-doc.org. Accessed December 20, 2006.
15. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
16. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cuddowicz ME. Neuroprotective agents for clinical trials in ALS. Neurology. 2006;67:20-27.
17. Huntington Project. Available at: http://www.huntingtonproject.org. Accessed December 20, 2006.
18. Palesch YY, Tilley BC, Sackett DL, Johnston KC, Woolson R. Applying a Phase II futility study design to therapeutic stroke trials. Stroke. 2005; 36:2410-2414.
19. The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke. 2004;35:904-911.
20. Virtual International Stroke Trials Archive. Available at: http://www.vista.gla.ac.uk/index.aspx. Accessed December 20, 2006.
21. Barak S, Duncan PW. Issues in selection outcome measure to assess functional recovery after stroke. NeuroRx. 2006;3:505-524.
22. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener H-C, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewksi WW; for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
23. Anonymous. Neurprotection: the end of an era? [Editorial]. The Lancet. 2006;368:1558.